Multicenter randomized double-blind controlled phase III study of hhpg-19K as prophylactic therapy in patients with advanced non-small cell lung cancer (NSCLC) receiving myelosuppressive chemotherapy.

Caicun Zhou, Jielai Xia, Changshan An et al.|Journal of Clinical Oncology|2014

Cited by 0